Comparison of triamcinolone with pentoxifylline and vitamin E efficacy in the treatment of stage 2 and 3 oral submucous fibrosis: A randomized clinical trial

• Published in: SAGE open medicine Vol. 11; p. 20503121231200757
• Main Authors: Shah, Saeed Ullah, Nigar, Seeme, Yousofi, Rahima, Maqsood, Afsheen, Altamash, Sara, lal, Abhishek, Khan, Zarak, Ahmed, Naseer, Heboyan, Artak
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-01-2023; Sage Publications Ltd; SAGE Publishing
• Subjects: Original; Vitamin E; pentoxifylline; Triamcinolone; oral submucosa fibrosis; tumor; vitamin E
• ISSN: 2050-3121; 2050-3121
• DOI: 10.1177/20503121231200757

Objective:
The objective of this study was to assess the effectiveness of triamcinolone in combination with pentoxifylline and vitamin E in the treatment of patients with level two and three oral submucous fibrosis.
Methods:
The study aimed to compare the efficacy of corticosteroid injections (triamcinolone) versus pentoxifylline and vitamin E in the therapy of patients with stage two and three oral submucous fibrosis. A total of 42 participants with indications and features of oral submucous fibrosis were enrolled between January 2020 and September 2021. The patients’ age and mouth opening were evaluated, and descriptive statistics and paired t-test were used for analytical investigation.
Results:
The study showed a statistically significant improvement in both treatment groups (p = 0.001) concerning pre- and post-treatment deviations. However, when comparing the standard differences in treatment outcomes between the two study groups, only mouth opening exhibited a statistically significant difference (p = 0.001).
Conclusions:
The findings indicate that a treatment regimen combining pentoxifylline and triamcinolone can significantly alleviate oral submucous fibrosis symptoms, including mouth opening, pain, and flaring agitation, thereby enhancing the affected individual’s quality of life.